Datroway's safety profile remains consistent, with 4.2% ILD rate; most cases were low ... approved AstraZeneca Plc’s AZN Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with ...

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Paget Disease of Bone. According to GlobalData, Phase I drugs for Paget Disease of Bone does not ...

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase ...

Jan. 9, 2025 — Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors. This could help ...

In the DATROWAY arm, the interstitial lung disease (ILD ... diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca and Daiichi Sankyo ...

WILMINGTON, Del., January 17, 2025--(BUSINESS WIRE)--DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone ...

In the DATROWAY arm, the interstitial lung disease (ILD) rate was 4.2% and the majority of events were low grade ... mechanisms of action to address the biologically diverse breast cancer tumor ...

raludotatug deruxtecan, DS-3939 and DS-9606 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established. DATROWAY can ...

In the DATROWAY arm, the interstitial lung disease (ILD ... collaboration to jointly develop and commercialize fam-trastuzumab deruxtecan-nxki in March 2019 and DATROWAY in July 2020, except ...

WILMINGTON, Del., January 17, 2025--(BUSINESS WIRE)--DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic ...